• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CVS Health Corporation

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $CVS alert in real time by email
    SC 13G 1 d793980dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 0 )*

     

     

    CVS HEALTH CORPORATION

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    126650100

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    PAGE 1 OF 5 PAGES


    CUSIP NO. 126650100    13G    PAGE 2 OF 5 PAGES

     

     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Dodge & Cox   94-1441976

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     N/A

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     California - U.S.A.

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     59,793,915

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     63,030,690

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     63,030,690

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     N/A

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.0%

    12  

     TYPE OF REPORTING PERSON*

     

     IA

     

    PAGE 2 OF 5 PAGES


    Item 1(a)

    Name of Issuer:

    CVS HEALTH CORPORATION

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    One CVS Drive

    Woonsocket, Rhode Island 02895

     

    Item 2(a)

    Name of Person Filing:

    Dodge & Cox

     

    Item 2(b)

    Address of the Principal Office or, if none, Residence:

    555 California Street, 40th Floor

    San Francisco, CA 94104

     

    Item 2(c)

    Citizenship:

    California - U.S.A.

     

    Item 2(d)

    Title of Class of Securities:

    Common Stock

     

    Item 2(e)

    CUSIP Number:

    126650100

     

    Item 3

    If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     

      (e)

    ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

     

    Item 4

    Ownership:

     

      (a)

    Amount Beneficially Owned:

    63,030,690

     

      (b)

    Percent of Class:

    5.0%

     

    PAGE 3 OF 5 PAGES


      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or direct the vote:

    59,793,915

     

      (ii)

    shared power to vote or direct the vote:

    0

     

      (iii)

    sole power to dispose or to direct the disposition of: 63,030,690

     

      (iv)

    shared power to dispose or to direct the disposition of: 0

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, CVS HEALTH CORPORATION.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9

    Notice of Dissolution of a Group:

    Not applicable.

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

     

    PAGE 4 OF 5 PAGES


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 13, 2024

     

    DODGE & COX
    By:  

    /S/ Katherine M. Primas

    Name:   Katherine M. Primas
    Title:   Chief Compliance Officer

     

    PAGE 5 OF 5 PAGES

    Get the next $CVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVS

    DatePrice TargetRatingAnalyst
    10/14/2025$91.00Buy
    Goldman
    8/18/2025$79.00Neutral → Buy
    UBS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    1/30/2025Hold → Buy
    Edward Jones
    12/3/2024$66.00Hold → Buy
    Deutsche Bank
    11/18/2024$60.00 → $66.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on CVS Health with a new price target

    Goldman initiated coverage of CVS Health with a rating of Buy and set a new price target of $91.00

    10/14/25 8:48:20 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by UBS with a new price target

    UBS upgraded CVS Health from Neutral to Buy and set a new price target of $79.00

    8/18/25 8:45:28 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded CVS Health from Neutral to Outperform and set a new price target of $82.00

    8/14/25 8:02:24 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Pharmacy completes acquisition of Rite Aid assets nationwide

    Company wraps up conversion of 63 former Rite Aid and Bartell Drugs stores in the Pacific Northwest and hundreds of prescription file buys across 15 states WOONSOCKET, R.I., Oct. 15, 2025 /PRNewswire/ -- CVS Pharmacy today announced the completion of its acquisition of select Rite Aid assets nationwide. In total, the company acquired and is now operating 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon and Washington. CVS Pharmacy also acquired the prescription files of 626 former Rite Aid and Bartell Drugs pharmacies in 15 states. As a result of the transactions, CVS Pharmacy is pleased to be serving more than nine million former Rite Aid and Bartell Drugs patients.

    10/15/25 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health® 2025 Rx Report highlights transformation of community pharmacy to meet patient needs

    CVS Health/Morning Consult survey reveals patients trust and prefer local pharmacy care, want expanded services in community pharmacy Number of pharmacy technicians who want to become pharmacists has increased significantly since 2024 WOONSOCKET, R.I., Oct. 14, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today released the 2025 Rx Report: Community Pharmacy Reimagined, which explores how community pharmacies are adapting to meet patient demand while supporting pharmacy teams and addressing industry challenges with sustainable models of care. "As one of the most trusted health

    10/14/25 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    SEC Filings

    View All

    SEC Form 8-K filed by CVS Health Corporation

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    9/22/25 4:19:42 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 144 filed by CVS Health Corporation

    144 - CVS HEALTH Corp (0000064803) (Subject)

    8/19/25 6:57:22 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 8-K filed by CVS Health Corporation

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    8/15/25 4:10:49 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Mahoney Michael F bought $2,001,000 worth of shares (30,000 units at $66.70), increasing direct ownership by 321% to 39,356 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    2/19/25 12:35:35 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: New insider Capozzi Heidi B claimed ownership of 5 shares (SEC Form 3)

    3/A - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:06:56 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Group President Shah Prem S covered exercise/tax liability with 6,995 shares, decreasing direct ownership by 10% to 60,632 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    9/2/25 4:42:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Aetna 2026 Medicare Advantage plans deliver access to affordable, personalized care

    Providing access to affordable care $0 copays on Tier 1 drugs & covered vaccines at in-network pharmacies1, $0 copay for colonoscopies and mammograms at in-network providers$0 copay for annual Healthy Home Visit from a licensed Signify Health clinicianContinued investment in technology, tools and teams that support our members Commitment to supporting unique member needs — those living with chronic conditions and individuals dually eligible for both Medicare and MedicaidLeveraging the strength of the CVS Health family of companies to deliver differentiated member experiencesWOONSOCKET, R.I., Oct. 1, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announced our 2026 Medi

    10/1/25 7:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

    WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res

    4/8/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Financials

    Live finance-specific insights

    View All

    CVS Pharmacy completes acquisition of Rite Aid assets nationwide

    Company wraps up conversion of 63 former Rite Aid and Bartell Drugs stores in the Pacific Northwest and hundreds of prescription file buys across 15 states WOONSOCKET, R.I., Oct. 15, 2025 /PRNewswire/ -- CVS Pharmacy today announced the completion of its acquisition of select Rite Aid assets nationwide. In total, the company acquired and is now operating 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon and Washington. CVS Pharmacy also acquired the prescription files of 626 former Rite Aid and Bartell Drugs pharmacies in 15 states. As a result of the transactions, CVS Pharmacy is pleased to be serving more than nine million former Rite Aid and Bartell Drugs patients.

    10/15/25 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health to hold third quarter 2025 earnings conference call

    WOONSOCKET, R.I., Sept. 30, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, October 29th, 2025, at 8:00 a.m. ET to discuss third quarter 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of June 30, 2025,

    9/30/25 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., Sept. 17, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on November 3, 2025, to holders of record on October 23, 2025. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of June 30, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and prima

    9/17/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/13/24 5:02:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/9/23 11:16:32 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples